[Blood coagulation factors and proteinase inhibitors in cytostatic therapy of acute leukemia].
In 64 patients affected with acute leukaemia (51 patients with acute non-lymphatic leukaemia and 13 patients with acute lymphatic leukaemia) extensive investigations of blood coagulation were made during cytostatic therapy. The following conspicuous changes of haemostatasis could be observed in making the diagnosis: Lowered quick value and shortened PTT, increased fibrinogen, fibrinopeptide, A, alpha 1-antitrypsin and alpha 2-macroglobulin, diminished plasminogen and plasma fibrininectin. According to TAD (VP) protocol the induction therapy leads to hypercoagulability which can be recognized by an increase of fibrinopeptide A, coagulating factors and shortening of PTT. During the therapy with L-asparaginasis procoagulatoric as well as thromboprotective coagulating proteins are diminished. A dense laboratory control enables those disturbances of haemotasis caused by disease or therapy to be separated and contributes to preventing complications during the cytostatic induction therapy.
Anders
O
O
Klinik für Innere Medizin, Bereiches Medizin der Wilhelm-Pieck-Universität Rostock.
Nagel
H R
HR
Ernst
B
B
Konrad
H
H
Zgola
M
M
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001779:Blood Coagulation Factors / Q000378:metabolism*; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy*; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000188:drug therapy*; D011480:Protease Inhibitors / Q000097:blood*; D012074:Remission Induction
D001779:Blood Coagulation Factors; D011480:Protease Inhibitors
Gerinnungsfaktoren und Proteinase-Inhibitoren während der zytostatischen Therapie der akuten Leukämie.